Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment Webcast 058IC (2018)
We will discuss common PSA dilemmas: 1. Who should be screened? 2. What is the role of MRI in biopsy naive and men with prior negative biopsy? 3. What other markers can be used to determine whether biopsy or rebiopsy is warranted? 4. Whats the optimal biopsy strategy: Transrectal, transperineal, MRI-cognitive, MRI fusion? 5. Discuss Active Surveillance, Rad Px, XRT and focal therapy pros and cons for PSA-detected cancer. 6. What is role of adjuvant v. salvage XRT post-RP? 7. Review new PET scans for biochemically recurrent disease after RP or XRT. 8. Discuss roles of ADT, chemotherapy, and other agents (PARP inhibitors, vaccines, immunooncologic agents) in men with advanced and metastatic disease.
This educational series is supported by independent educational grants from:
- Genomic Health
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Medivation, Inc. a Pfizer company
- Sanofi Genzyme.
- Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
After completing this activity, participants will be able to:
- Use shared decision making to test men with PSA, to decide whom to biopsy and how to biopsy
- Understand the pros and cons of different types of biopsy and how to select men for surveillance, surgery or XRT
- Determine the new therapies for advanced and metastatic cancer with ADT, chemo, and immunotherapies
- Identify the roles of new staging PET scans
Gerald Andriole, Jr., MD: Augmenix: Consultant or Advisor, Other; Medivation: Scientific Study or Trial; Blue Earth Diagnostics: Scientific Study or Trial; Progenics: Scientific Study or Trial; Tolmar Pharmaceuticals: Consultant or Advisor; 3D Biopsy: Consultant or Advisor
Anthony D'Amico, MD, PhD: Nothing to disclose.
Adam Kibel, MD: Profound: Consultant or Advisor; Janssen: Consultant or Advisor; ConfirmMDx: Consultant or Advisor; Pfizer: Consultant or Advisor
Oliver Sartor, MD: Nothing to disclose.
Method of Participation
To claim CME credit/hours of participation, the learner must view the webcast, complete the post-test passing with 80% accuracy and submit the activity evaluation.
Estimated time to complete this activity: 2.00 hour
Release Date: June, 2018
Expiration Date: June, 2019
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1.00 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Acknowledgements: Support provided by an independent education grant from AbbVie, Astellas, Genomic Health, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Medivation, Inc. a Pfizer company and Sanofi Genzyme.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation